Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.60 |
| ▸ | GRM6 | O15303 | 1/20 | 0.60 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.60 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.60 |
| ▸ | GSR | P00390 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.60 |
| ▸ | GRM5 | P41594 | 1/20 | 0.60 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.60 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.60 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.60 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.60 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.60 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.60 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.60 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.60 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.60 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.60 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27741548 | 1.00 | GRM8 (0.60) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL709482 | 0.82 | GRM8 (0.60) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL21447963 | 0.82 | BLM (0.58) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL709483 | 0.82 | GRM8 (0.60) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL4321248 | 0.82 | BLM (0.58) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL24140515 | 0.80 | GRM8 (0.58) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL85942 | 0.80 | GRM8 (0.58) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL9021158 | 0.80 | GRM8 (0.58) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL9304411 | 0.80 | GRM8 (0.58) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL8763003 | 0.80 | GRM8 (0.58) | GRM8GRM6GRIN2DGRIN3BGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101163-A1 | COMPOSITION FOR INHIBITING CANCER METASTASIS | TAIPEI MEDICAL UNIVERSITY (TW) | 2012-04-26 | — | — | US | claimed |
| US-20240182961-A1 | Method to Screen For a Mutant Within a Population of Organisms By Applying a Pooling and Splitting Approach | CARLSBERG A/S (DK) | 2024-06-06 | — | — | US | disclosed |
| US-11884972-B2 | Method to screen for a mutant within a population of organisms by applying a pooling and splitting approach | CARLSBERG A/S (DK) | 2024-01-30 | — | — | US | disclosed |
| CN-116836885-A | Corynebacterium glutamicum and application thereof in production of L-glutamic acid | 欧铭庄生物科技(天津)有限公司滨海新区分公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-4118194-A1 | TRANSGLUTAMINASE VARIANTS | Curie Co. Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| CN-115605588-A | Transglutaminase variants and uses thereof | 居里公司（US） | 2023-01-13 | — | — | CN | disclosed |
| CN-115210368-A | Cell-free protein expression of mature polypeptides derived from proenzymes and proproteins | 居里公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-114959098-A | Method for screening mutants in biological populations by applying mixed division method | 嘉士伯有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-109477087-B | Method for screening mutants in biological populations by applying mixed division method | 嘉士伯有限公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-3478832-B1 | METHOD TO SCREEN FOR A MUTANT WITHIN A POPULATION OF ORGANISMS BY APPLYING A POOLING AND SPLITTING APPROACH | CARLSBERG AS (DK) | 2022-02-23 | — | — | EP | disclosed |
| US-20120035264-A1 | Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response | BERNARDI, PAOLO (IT) | 2012-02-09 | — | — | US | disclosed |
| WO-2009094212-A1 | DIAGNOSTIC ASSAY FOR DETECTION OF ACTIVE TUBERCULOSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-30 | — | — | WO | disclosed |
| EP-2008210-A1 | MODULATION OF PHOSPHORYL TRANSFERASE ACTIVITY OF GLUTAMINE SYNTHETASE | CSIR (ZA) | 2008-12-31 | — | — | EP | disclosed |
| EP-1965778-A2 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NewThera (FR) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007105023-A1 | MODULATION OF PHOSPHORYL TRANSFERASE ACTIVITY OF GLUTAMINE SYNTHETASE | CSIR (ZA) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007017768-A2 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2007-02-15 | — | — | WO | disclosed |
| WO-1998017307-A1 | METHOD AND COMPOSITION FOR TREATING NEURONAL DEGENERATION | RAMOT-UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT, LTD. (IL) | 1998-04-30 | — | — | WO | disclosed |
| EP-0436612-A4 | AMINO ACID TRANSPORT PROTEINS, AMINO ACID ANALOGUES, ASSAY APPARATUS, USES THEREOF FOR TREATMENT AND DIAGNOSIS OF CANCER | — | 1992-05-20 | — | — | EP | disclosed |
| EP-0436612-A1 | AMINO ACID TRANSPORT PROTEINS, AMINO ACID ANALOGUES, ASSAY APPARATUS, USES THEREOF FOR TREATMENT AND DIAGNOSIS OF CANCER | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1991-07-17 | — | — | EP | disclosed |
| WO-1990003399-A1 | AMINO ACID TRANSPORT PROTEINS, AMINO ACID ANALOGUES, ASSAY APPARATUS, USES THEREOF FOR TREATMENT AND DIAGNOSIS OF CANCER | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1990-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035264-A1 | Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response | MTR, MSRB3, DDO | GRM8 209/4885GRM6 106/4885GRIN2D 1844/4885 |
| US-20120101163-A1 | COMPOSITION FOR INHIBITING CANCER METASTASIS | HDGF, MIF, HGF | GRM8 3020/4885GRM6 594/4885GRIN2D 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.